Prednison 50 mg GALEN® clinical trials

C5691004 _ A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

This study is testing a new way to treat a type of cancer called peripheral T-cell lymphoma (PTCL). Researchers want to see if combining a newer drug (brentuximab vedotin) with standard chemotherapy (CHP) works well for people with a specific type of PTCL.